What is Beta Bionics, Inc. Common Stock's market cap?

Beta Bionics, Inc. Common Stock (BBNX) has a market capitalization of $709.0M and trades on NASDAQ.

What is Beta Bionics, Inc. Common Stock's revenue and profitability?

Beta Bionics, Inc. Common Stock generated $110.2M in trailing twelve-month revenue with a net loss of $66.4M, representing a net margin of -60.3%. Gross margin stands at 57.2%, with free cash flow of -$61.1M. These figures are based on the Q1 2026 filing.

Who are Beta Bionics, Inc. Common Stock's competitors?

Beta Bionics, Inc. Common Stock's key competitors include Tandem Diabetes Care, Insulet, Medtronic, and others. These companies compete in similar markets and product categories.

Who does Beta Bionics, Inc. Common Stock partner with?

Beta Bionics, Inc. Common Stock's notable partners include DexCom, Abbott Laboratories, Xeris Pharmaceuticals, and others.

Where is Beta Bionics, Inc. Common Stock headquartered?

Beta Bionics, Inc. Common Stock is headquartered in United States of America. It has been publicly traded since 2025.

Beta Bionics, Inc. Common Stock

BBNX

Beta Bionics is a commercial-stage medical device company that develops and commercializes automated insulin delivery systems for people with diabetes.

Market cap

$708.98M+9.1%

Revenue$110.2M+57.9%

Net income-$66.4M+6.4%

Free cash flow-$61.1M-2.9%

EPS (diluted)-$1.50+80.0%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

April 21, 2026

Revenue$27.6MBeat by $678.2K EPS-$0.49Beat by $0.04

Read the full report

Next report

Aug 4, 2026 (in a month)

Revenue estimate$31.5M

EPS estimate-$0.62

Financials

Q1 2026

Income statement

See full

Revenue$27.6M+56.6%

Gross profit$16.4M+83.2%

Operating income-$24.3M-30.2%

Net income-$21.9M+23.6%

EPS (diluted)-$0.49+47.3%

Balance sheet

See full

Cash & equivalents$30.2M-28.9%

Total debt$6.9M-0.9%

Total equity$271.2M-13.5%

Total assets$304.4M-9.9%

Cash flow

See full

Operating cash flow-$23.8M-19.3%

CapEx$1.4M+314%

Free cash flow-$25.2M-24.1%

Valuation & ratios

Valuation

See full

Market cap$708.98M+9.1%

Enterprise value$685.68M—

P/S6.4×—

Profitability

See full

Gross margin57.2%+3.2pp

Operating margin-70.1%-6.4pp

Net margin-60.3%-17.4pp

FCF margin-55.4%-14.3pp

Returns & leverage

See full

Return on equity-22.7%—

Debt / equity0×0.0×

Current ratio10.7×-5.2×

Segments

By product

See full

Single Use Products$10.2M+144%

I Let$10.1M+4.8%

By geography

See full

Non Us-—

Competitors

By market cap

Medtronic$103.07B

Insulet$10.7B

Halozyme Therapeutics$8.6B

AdaptHealth$1.4B

Tandem Diabetes Care$1.1B

Beta Bionics, Inc. Common Stock$709.0M

By revenue growth

Beta Bionics, Inc. Common Stock+57.9%

Halozyme Therapeutics+39.1%

Insulet+31.9%

Medtronic+8.4%

Tandem Diabetes Care+4.5%

AdaptHealth+1.2%

By net margin

Halozyme Therapeutics47.91%

Medtronic13.2%

Insulet10.44%

AdaptHealth-2.42%

Tandem Diabetes Care-9.2%

Beta Bionics, Inc. Common Stock-60.27%

Profile

Beta Bionics is a commercial-stage medical device company that develops and commercializes automated insulin delivery systems for people with diabetes. Its core value proposition is the iLet Bionic Pancreas, a fully closed-loop system that utilizes adaptive algorithms to autonomously determine and deliver all insulin doses, significantly reducing the cognitive and manual burden of disease management.

Competitive position

Beta Bionics is a pioneer in the 'true fully closed-loop' category, offering the only FDA-cleared device that eliminates carbohydrate counting and manual bolus calculations.

GeographiesUnited States

Customer segmentsPatients, Healthcare Providers, Insurance Payors

Business modelManufacturing, Direct-to-Consumer, Recurring Revenue

SuppliersComponent and subassembly suppliers, Continuous Glucose Monitor (CGM) manufacturers, Insulin manufacturers

CustomersType 1 diabetes patients, Endocrinology clinics, Independent medical distributors, Pharmacy benefit managers

CountryUnited States of America

Listed2025

CEOSean T. Saint

Websitebetabionics.com

FilingsSEC EDGAR

Ask your AI about Beta Bionics, Inc. Common Stock.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Beta Bionics, Inc. Common Stock's market cap?: Beta Bionics, Inc. Common Stock (BBNX) has a market capitalization of $709.0M and trades on NASDAQ.
What is Beta Bionics, Inc. Common Stock's revenue and profitability?: Beta Bionics, Inc. Common Stock generated $110.2M in trailing twelve-month revenue with a net loss of $66.4M, representing a net margin of -60.3%. Gross margin stands at 57.2%, with free cash flow of -$61.1M. These figures are based on the Q1 2026 filing.
Who are Beta Bionics, Inc. Common Stock's competitors?: Beta Bionics, Inc. Common Stock's key competitors include Tandem Diabetes Care, Insulet, Medtronic, and others. These companies compete in similar markets and product categories.
Who does Beta Bionics, Inc. Common Stock partner with?: Beta Bionics, Inc. Common Stock's notable partners include DexCom, Abbott Laboratories, Xeris Pharmaceuticals, and others.
Where is Beta Bionics, Inc. Common Stock headquartered?: Beta Bionics, Inc. Common Stock is headquartered in United States of America. It has been publicly traded since 2025.